Menarini is present in 136 countries world-wide and continues to invest heavily in Italy: out of 17,000 Group employees, more than 3,700 work in Italy, almost 300 of them hired over the last two years and work in the Group's Florentine headquarters.
Menarini Biomarkers Singapore (MBS) - was created in 2014 by Menarini Asia- Pacific and is fully owned by the Menarini Group, the world's largest Italian biopharmaceutical company with annual revenue exceeding 3.6 billion euros (2017). Founded in 1886, Menarini has grown to encompass over 17,000 employees working in more than 130 countries today and possess an- extensive brands portfolio consisting of products in the key therapeutic of aesthetics, allergy/respiratory, cardiovascular, consumer healthcare, dermatology, gastro intestinal, men's health and pain management.
Menarini Biomarkers Singapore's mission is to identify, develop and validate new biomarkers on circulating human cells for applications in diagnostics.
Many novel biomarkers will be identified using single cells analysis in the coming years. These discoveries will drive precision medicine, the new frontier in disease prediction and disease control. From liquid biopsies, circulating cells such as CFC (circulating fetal cells), CTC (circulating tumor cells) and PIC (pathogenic immune cells) will be captured by specific antibodies developed against novel targets, conjugated to FerroFluid (Cell Search Technology) and further selected and analysed using the DEPArray platform . Together with Menarini Silicon Biosystems (MSB), BiomarkersMBS aims to recover and select the most rarerarest cell types from any type of tissues or liquid biopsies. The identified novel biomarkers will provide new tools and actionable insights fort clinicians to track disease progression and measure real-time responses to therapies.
For more information, please visit the Menarini Biomarkers Singapore.